临床肺科杂志
臨床肺科雜誌
림상폐과잡지
JOUNAL OF CLINICAL PULMONARY MEDICINE
2015年
6期
1112-1113,1114
,共3页
环磷腺苷葡胺%丹参酮ⅡA磺酸钠%肺心病%血液流变学%疗效
環燐腺苷葡胺%丹參酮ⅡA磺痠鈉%肺心病%血液流變學%療效
배린선감포알%단삼동ⅡA광산납%폐심병%혈액류변학%료효
meglumine cyclic adenosine monophosphate%sodium tanshinon ⅡA silate%pulmonary heart disease%hemorheology%efficacy
目的:探讨环磷腺苷葡胺+丹参酮ⅡA磺酸钠治疗肺心病的临床疗效。方法以2011年2月至2013年1月我院收治的74例肺心病患者为研究对象,分为治疗组和对照组,治疗组给予环磷腺苷葡胺+丹参酮ⅡA磺酸钠,对照组进行常规治疗。比较两组的临床疗效,观察两组患者治疗前后血液流变学指标。结果治疗组总有效率为91.89%,对照组总有效率为83.78%。两组各项血液流变学指标较治疗前均明显改善,以治疗组效果更佳。治疗结束后,治疗组患者心功能得到明显改善,较对照组更佳。以上差异均具有统计学意义(P<0.05)。结论采用环磷腺苷葡胺+丹参酮ⅡA磺酸钠治疗肺心病,可有效改善患者血液流变学指标,临床疗效显著。
目的:探討環燐腺苷葡胺+丹參酮ⅡA磺痠鈉治療肺心病的臨床療效。方法以2011年2月至2013年1月我院收治的74例肺心病患者為研究對象,分為治療組和對照組,治療組給予環燐腺苷葡胺+丹參酮ⅡA磺痠鈉,對照組進行常規治療。比較兩組的臨床療效,觀察兩組患者治療前後血液流變學指標。結果治療組總有效率為91.89%,對照組總有效率為83.78%。兩組各項血液流變學指標較治療前均明顯改善,以治療組效果更佳。治療結束後,治療組患者心功能得到明顯改善,較對照組更佳。以上差異均具有統計學意義(P<0.05)。結論採用環燐腺苷葡胺+丹參酮ⅡA磺痠鈉治療肺心病,可有效改善患者血液流變學指標,臨床療效顯著。
목적:탐토배린선감포알+단삼동ⅡA광산납치료폐심병적림상료효。방법이2011년2월지2013년1월아원수치적74례폐심병환자위연구대상,분위치료조화대조조,치료조급여배린선감포알+단삼동ⅡA광산납,대조조진행상규치료。비교량조적림상료효,관찰량조환자치료전후혈액류변학지표。결과치료조총유효솔위91.89%,대조조총유효솔위83.78%。량조각항혈액류변학지표교치료전균명현개선,이치료조효과경가。치료결속후,치료조환자심공능득도명현개선,교대조조경가。이상차이균구유통계학의의(P<0.05)。결론채용배린선감포알+단삼동ⅡA광산납치료폐심병,가유효개선환자혈액류변학지표,림상료효현저。
Objective To investigate the clinical efficacy of meglumine cyclic adenosine monophosphate combined with sodium tanshinon ⅡA silate in the treatment of pulmonary heart disease. Methods From February 2011 to January 2013 in our hospital, 74 patients with pulmonary heart disease were randomly divided into the treat-ment group and the control group. The treatment group received meglumine cyclic adenosine monophosphate com-bined with sodium tanshinon ⅡA silate, and the control group was given conventional therapy. The clinical efficacy was compared between the two groups before and after the treatment. Results The total effective rate was 91. 89%in the treatment group and 83. 78% in the control group. Hemorheology and heart function improved after the treat-ment in the two groups, and the improvement was more pronounced in the treatment group than in the control group (P<0. 05). Conclusion The application of meglumine cyclic adenosine monophosphate and sodium tanshinonⅡA silate can effectively improve their hemorheology and heart function in the treatment of patients with pulmonary heart disease.